Clinical Trial Update: Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine and rituximab followed by 90-yttrium ibritumomab tiuxetan for untreated follicular lymphoma has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Zytiga? 90-yttrium (Y) ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Lymphoma, Follicular | Phase 2 | Status: COMPLETED | Results posted: 2018-05-14